{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:56:39Z","timestamp":1793656599973,"version":"4.5.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-025-04110-0","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:33:18Z","timestamp":1763429598000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in immune microenvironment profiling during multiple myeloma progression and therapy"],"prefix":"10.1007","volume":"124","author":[{"given":"Junzhe","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8269-440X","authenticated-orcid":false,"given":"Yawara","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"5","key":"4110_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"8","key":"4110_CR2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/ijc.34609","volume":"153","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao X, Shen H, Liu X, Xu X, Fu R. Cellular immunity in the era of modern multiple myeloma therapy. Int J Cancer. 2023;153(8):1436\u201347. https:\/\/doi.org\/10.1002\/ijc.34609.","journal-title":"Int J Cancer"},{"issue":"13","key":"4110_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2023022499","volume":"143","author":"H Lee","year":"2024","unstructured":"Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024;143(13):1211\u20137.","journal-title":"Blood"},{"issue":"1","key":"4110_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/hematology.2023000433","volume":"2023","author":"H Lee","year":"2023","unstructured":"Lee H, Neri P, Bahlis NJ. Current use of bispecific antibodies to treat multiple myeloma. Hematol Am Soc Hematol Educ Program. 2023;2023(1):332\u20139. https:\/\/doi.org\/10.1182\/hematology.2023000433.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"4110_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302\u201318.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"4110_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1):160\u201372. https:\/\/doi.org\/10.1111\/imr.12233.","journal-title":"Immunol Rev"},{"issue":"4","key":"4110_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330\u20136.","journal-title":"Nat Immunol"},{"key":"4110_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0065-230X(10)07003-X","volume":"107","author":"D Mougiakakos","year":"2010","unstructured":"Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory t cells in cancer. Adv Cancer Res. 2010;107:57\u2013117.","journal-title":"Adv Cancer Res"},{"issue":"4","key":"4110_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ijc.25429","volume":"127","author":"H Nishikawa","year":"2010","unstructured":"Nishikawa H, Sakaguchi S. Regulatory t cells in tumor immunity. Int J Cancer. 2010;127(4):759\u201367. https:\/\/doi.org\/10.1002\/ijc.25429.","journal-title":"Int J Cancer"},{"issue":"6","key":"4110_CR10","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1172\/JCI88169","volume":"128","author":"Y Kawano","year":"2018","unstructured":"Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018;128(6):2487\u201399.","journal-title":"J Clin Invest"},{"issue":"5","key":"4110_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493\u2013506.","journal-title":"Nat Cancer"},{"issue":"1","key":"4110_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14(1):194.","journal-title":"Blood Cancer J"},{"key":"4110_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12935-018-0687-8","volume":"18","author":"JN Wang","year":"2018","unstructured":"Wang JN, Cao XX, Zhao AL, Cai H, Wang X, Li J. Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study. Cancer Cell Int. 2018;18:187.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"4110_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","volume":"63","author":"WM Braga","year":"2014","unstructured":"Braga WM, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, et al. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother. 2014;63(11):1189\u201397.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"4110_CR15","doi-asserted-by":"publisher","first-page":"e49446","DOI":"10.1371\/journal.pone.0049446","volume":"7","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, et al. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS ONE. 2012;7(11):e49446. https:\/\/doi.org\/10.1371\/journal.pone.0049446.","journal-title":"PLoS ONE"},{"issue":"5","key":"4110_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","volume":"144","author":"S Feyler","year":"2009","unstructured":"Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol. 2009;144(5):686\u201395.","journal-title":"Br J Haematol"},{"issue":"13","key":"4110_CR17","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","volume":"26","author":"N Alrasheed","year":"2020","unstructured":"Alrasheed N, Lee L, Ghorani E, Henry JY, Conde L, Chin M, et al. Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4(+)PD-1(+) cells and inferior survival in patients with newly diagnosed multiple myeloma. Clin Cancer Res. 2020;26(13):3443\u201354.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4110_CR18","doi-asserted-by":"publisher","first-page":"e35981","DOI":"10.1371\/journal.pone.0035981","volume":"7","author":"S Feyler","year":"2012","unstructured":"Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS ONE. 2012;7(5):e35981. https:\/\/doi.org\/10.1371\/journal.pone.0035981.","journal-title":"PLoS ONE"},{"issue":"1","key":"4110_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","volume":"166","author":"B Almand","year":"2001","unstructured":"Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678\u201389. https:\/\/doi.org\/10.4049\/jimmunol.166.1.678.","journal-title":"J Immunol"},{"issue":"1","key":"4110_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49\u201359.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"4110_CR21","doi-asserted-by":"publisher","first-page":"10532","DOI":"10.18632\/oncotarget.3300","volume":"6","author":"K De Veirman","year":"2015","unstructured":"De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, et al. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget. 2015;6(12):10532\u201347.","journal-title":"Oncotarget"},{"issue":"11","key":"4110_CR22","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/leu.2012.113","volume":"26","author":"E Van Valckenborgh","year":"2012","unstructured":"Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, Menu E, De Baetselier P, et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia. 2012;26(11):2424\u20138.","journal-title":"Leukemia"},{"issue":"4","key":"4110_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","volume":"33","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Kassem S, Cleynen A, Chretien ML, Guillerey C, Putz EM, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018;33(4):634\u2013485.","journal-title":"Cancer Cell"},{"issue":"6","key":"4110_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","volume":"72","author":"MK Brimnes","year":"2010","unstructured":"Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010;72(6):540\u20137. https:\/\/doi.org\/10.1111\/j.1365-3083.2010.02463.x.","journal-title":"Scand J Immunol"},{"issue":"15","key":"4110_CR25","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","volume":"121","author":"GT Gorgun","year":"2013","unstructured":"Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121(15):2975\u201387. https:\/\/doi.org\/10.1182\/blood-2012-08-448548.","journal-title":"Blood"},{"issue":"7","key":"4110_CR26","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","volume":"190","author":"IR Ramachandran","year":"2013","unstructured":"Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013;190(7):3815\u201323. https:\/\/doi.org\/10.4049\/jimmunol.1203373.","journal-title":"J Immunol"},{"issue":"2","key":"4110_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","volume":"136","author":"C Perez","year":"2020","unstructured":"Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199\u2013209.","journal-title":"Blood"},{"issue":"3","key":"4110_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/bjh.19049","volume":"203","author":"K Mizuhara","year":"2023","unstructured":"Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, et al. Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma. Br J Haematol. 2023;203(3):426\u201338.","journal-title":"Br J Haematol"},{"issue":"12","key":"4110_CR29","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","volume":"55","author":"J Favaloro","year":"2014","unstructured":"Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N, et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma. 2014;55(12):2893\u2013900. https:\/\/doi.org\/10.3109\/10428194.2014.904511.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4110_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bjh.18708","volume":"201","author":"J Li","year":"2023","unstructured":"Li J, Yang Y, Wang W, Xu J, Sun Y, Jiang J, et al. Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma. Br J Haematol. 2023;201(5):917\u201334.","journal-title":"Br J Haematol"},{"issue":"1","key":"4110_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41525-022-00340-x","volume":"8","author":"W Pilcher","year":"2023","unstructured":"Pilcher W, Thomas BE, Bhasin SS, Jayasinghe RG, Yao L, Gonzalez-Kozlova E, et al. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. NPJ Genom Med. 2023;8(1):3.","journal-title":"NPJ Genom Med"},{"key":"4110_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127807","author":"JK Bailur","year":"2019","unstructured":"Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, et al. Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.127807.","journal-title":"JCI Insight"},{"issue":"1","key":"4110_CR33","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1038\/s41467-023-41562-6","volume":"14","author":"C Botta","year":"2023","unstructured":"Botta C, Perez C, Larrayoz M, Puig N, Cedena MT, Termini R, et al. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance. Nat Commun. 2023;14(1):5825.","journal-title":"Nat Commun"},{"issue":"16","key":"4110_CR34","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","volume":"132","author":"SA Minnie","year":"2018","unstructured":"Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2018;132(16):1675\u201388.","journal-title":"Blood"},{"issue":"20","key":"4110_CR35","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood.2024024590","volume":"144","author":"M John","year":"2024","unstructured":"John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, et al. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024;144(20):2121\u201335.","journal-title":"Blood"},{"issue":"4","key":"4110_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/sj.leu.2404096","volume":"20","author":"C Fauriat","year":"2006","unstructured":"Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia. 2006;20(4):732\u20133.","journal-title":"Leukemia"},{"issue":"4","key":"4110_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0711293105","volume":"105","author":"M Jinushi","year":"2008","unstructured":"Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105(4):1285\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4110_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/imm.12082","volume":"139","author":"RT Costello","year":"2013","unstructured":"Costello RT, Boehrer A, Sanchez C, Mercier D, Baier C, Le Treut T, et al. Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology. 2013;139(3):338\u201341.","journal-title":"Immunology"},{"issue":"1","key":"4110_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","volume":"126","author":"K Lagrue","year":"2015","unstructured":"Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126(1):50\u201360.","journal-title":"Blood"},{"issue":"20","key":"4110_CR40","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G Gorgun","year":"2015","unstructured":"Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607\u201318.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"4110_CR41","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286\u201394.","journal-title":"Blood"},{"issue":"22","key":"4110_CR42","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-15-1320","volume":"75","author":"A Ponzetta","year":"2015","unstructured":"Ponzetta A, Benigni G, Antonangeli F, Sciume G, Sanseviero E, Zingoni A, et al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res. 2015;75(22):4766\u201377. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1320.","journal-title":"Cancer Res"},{"issue":"6673","key":"4110_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245\u201352.","journal-title":"Nature"},{"issue":"10","key":"4110_CR44","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","volume":"98","author":"RD Brown","year":"2001","unstructured":"Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7\u20131) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001;98(10):2992\u20138.","journal-title":"Blood"},{"issue":"12","key":"4110_CR45","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","volume":"126","author":"P Leone","year":"2015","unstructured":"Leone P, Berardi S, Frassanito MA, Ria R, De Re V, Cicco S, et al. Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood. 2015;126(12):1443\u201351.","journal-title":"Blood"},{"issue":"1","key":"4110_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","volume":"144","author":"MK Brimnes","year":"2006","unstructured":"Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol. 2006;144(1):76\u201384. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03037.x.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4110_CR47","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1182\/blood.V100.1.230","volume":"100","author":"M Ratta","year":"2002","unstructured":"Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100(1):230\u20137.","journal-title":"Blood"},{"issue":"6","key":"4110_CR48","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1182\/blood-2005-06-2486","volume":"107","author":"S Wang","year":"2006","unstructured":"Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood. 2006;107(6):2432\u20139.","journal-title":"Blood"},{"issue":"6","key":"4110_CR49","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","volume":"29","author":"A Ray","year":"2015","unstructured":"Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29(6):1441\u20134.","journal-title":"Leukemia"},{"issue":"2","key":"4110_CR50","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","volume":"66","author":"CE Lewis","year":"2006","unstructured":"Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605\u201312. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4005.","journal-title":"Cancer Res"},{"issue":"12","key":"4110_CR51","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677\u201386. https:\/\/doi.org\/10.1016\/j.it.2004.09.015.","journal-title":"Trends Immunol"},{"issue":"1","key":"4110_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39\u201351.","journal-title":"Cell"},{"issue":"5","key":"4110_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-012-1652-6","volume":"92","author":"E Suyani","year":"2013","unstructured":"Suyani E, Sucak GT, Akyurek N, Sahin S, Baysal NA, Yagci M, et al. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013;92(5):669\u201377.","journal-title":"Ann Hematol"},{"issue":"1","key":"4110_CR54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Geng X, Hou J, Wu G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21(1):389.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"4110_CR55","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","volume":"124","author":"C Berges","year":"2008","unstructured":"Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008;124(2):234\u201346.","journal-title":"Immunology"},{"issue":"9","key":"4110_CR56","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/imt.15.66","volume":"7","author":"ST Pellom Jr","year":"2015","unstructured":"Pellom ST Jr, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015;7(9):1011\u201322.","journal-title":"Immunotherapy"},{"issue":"6","key":"4110_CR57","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.4049\/jimmunol.1103826","volume":"189","author":"CL Chang","year":"2012","unstructured":"Chang CL, Hsu YT, Wu CC, Yang YC, Wang C, Wu TC, et al. Immune mechanism of the antitumor effects generated by bortezomib. J Immunol. 2012;189(6):3209\u201320. https:\/\/doi.org\/10.4049\/jimmunol.1103826.","journal-title":"J Immunol"},{"issue":"6","key":"4110_CR58","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00277-019-03657-3","volume":"98","author":"C Hadjiaggelidou","year":"2019","unstructured":"Hadjiaggelidou C, Mandala E, Terpos E, Yiannaki E, Markala D, Triantafyllou T, et al. Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Ann Hematol. 2019;98(6):1457\u201366.","journal-title":"Ann Hematol"},{"issue":"1","key":"4110_CR59","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12013-014-0224-x","volume":"71","author":"J Li","year":"2015","unstructured":"Li J, Li Y, Huang B, Zheng D, Chen M, Zhou Z. Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy. Cell Biochem Biophys. 2015;71(1):457\u201364.","journal-title":"Cell Biochem Biophys"},{"issue":"7","key":"4110_CR60","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood.2019003257","volume":"136","author":"RS Hesterberg","year":"2020","unstructured":"Hesterberg RS, Beatty MS, Han Y, Fernandez MR, Akuffo AA, Goodheart WE, et al. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes. Blood. 2020;136(7):857\u201370.","journal-title":"Blood"},{"issue":"6","key":"4110_CR61","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811\u201321.","journal-title":"Br J Haematol"},{"issue":"2","key":"4110_CR62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","volume":"41","author":"C Wolschke","year":"2013","unstructured":"Wolschke C, Stubig T, Hegenbart U, Schonland S, Heinzelmann M, Hildebrandt Y, et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study. Exp Hematol. 2013;41(2):134\u2013423.","journal-title":"Exp Hematol"},{"issue":"2","key":"4110_CR63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/bmt.2009.155","volume":"45","author":"M Lioznov","year":"2010","unstructured":"Lioznov M, El-Cheikh J Jr, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant. 2010;45(2):349\u201353.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4110_CR64","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41420-023-01765-8","volume":"9","author":"H Chen","year":"2023","unstructured":"Chen H, Wang X, Wang Y, Chang X. What happens to regulatory T cells in multiple myeloma. Cell Death Discov. 2023;9(1):468.","journal-title":"Cell Death Discov"},{"issue":"26","key":"4110_CR65","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","volume":"125","author":"K Sehgal","year":"2015","unstructured":"Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042\u201351.","journal-title":"Blood"},{"key":"4110_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.exphem.2016.11.004","volume":"46","author":"MC Vo","year":"2017","unstructured":"Vo MC, Anh-NguyenThi T, Lee HJ, Nguyen-Pham TN, Jaya Lakshmi T, Jung SH, et al. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. Exp Hematol. 2017;46:48\u201355.","journal-title":"Exp Hematol"},{"key":"4110_CR67","doi-asserted-by":"publisher","first-page":"1076096","DOI":"10.3389\/fphar.2022.1076096","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Dai J, Xia J, Ye Z, Huang X, Cao W, et al. Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients. Front Pharmacol. 2022;13:1076096.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4110_CR68","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.16881","volume":"191","author":"S Kuwahara-Ota","year":"2020","unstructured":"Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, et al. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. Br J Haematol. 2020;191(5):784\u201395.","journal-title":"Br J Haematol"},{"issue":"1","key":"4110_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13\u201329.","journal-title":"Blood"},{"issue":"3","key":"4110_CR70","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394.","journal-title":"Blood"},{"issue":"1","key":"4110_CR71","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.3324\/haematol.2019.219683","volume":"105","author":"A Kitadate","year":"2020","unstructured":"Kitadate A, Kobayashi H, Abe Y, Narita K, Miura D, Takeuchi M, et al. Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients. Haematologica. 2020;105(1):e37\u201340.","journal-title":"Haematologica"},{"issue":"23","key":"4110_CR72","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105\u201314.","journal-title":"Blood Adv"},{"issue":"1","key":"4110_CR73","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","volume":"35","author":"D Viola","year":"2021","unstructured":"Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia. 2021;35(1):189\u2013200.","journal-title":"Leukemia"},{"issue":"24","key":"4110_CR74","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"4110_CR75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"9","key":"4110_CR76","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"9","key":"4110_CR77","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"4","key":"4110_CR78","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41(4):711.","journal-title":"Cancer Cell"},{"key":"4110_CR79","doi-asserted-by":"publisher","first-page":"1613265","DOI":"10.3389\/fimmu.2025.1613265","volume":"16","author":"NT Iannozzi","year":"2025","unstructured":"Iannozzi NT, Giuliani N, Storti P. Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance. Front Immunol. 2025;16:1613265.","journal-title":"Front Immunol"},{"issue":"5","key":"4110_CR80","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407.","journal-title":"N Engl J Med"},{"issue":"10","key":"4110_CR81","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R de Montes Oca","year":"2021","unstructured":"de Montes Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941\u201355.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"4110_CR82","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1002\/ajh.26823","volume":"98","author":"IV Kostopoulos","year":"2023","unstructured":"Kostopoulos IV, Kakalis A, Birmpilis A, Angelis N, Orologas-Stavrou N, Rousakis P, et al. Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients. Am J Hematol. 2023;98(3):E65.","journal-title":"Am J Hematol"},{"issue":"10","key":"4110_CR83","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895\u2013905.","journal-title":"N Engl J Med"},{"key":"4110_CR84","doi-asserted-by":"publisher","first-page":"618610","DOI":"10.3389\/fimmu.2021.618610","volume":"12","author":"L Lee","year":"2021","unstructured":"Lee L, Alrasheed N, Khandelwal G, Fitzsimons E, Richards H, Wilson W, et al. Increased immune-regulatory receptor expression on effector T cells as early indicators of relapse following autologous stem cell transplantation for multiple myeloma. Front Immunol. 2021;12:618610.","journal-title":"Front Immunol"},{"issue":"1","key":"4110_CR85","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41598-024-84047-2","volume":"15","author":"K Chen","year":"2025","unstructured":"Chen K, Liang H, Yu Z, Guo G, Zheng H, Huang Y, et al. Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma. Sci Rep. 2025;15(1):1222.","journal-title":"Sci Rep"},{"issue":"6","key":"4110_CR86","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtct.2024.03.005","volume":"30","author":"S Richter","year":"2024","unstructured":"Richter S, Bottcher M, Stoll A, Zeremski V, Volkl S, Mackensen A, et al. Increased PD-1 expression on circulating T cells correlates with inferior outcome after autologous stem cell transplantation. Transplant Cell Ther. 2024;30(6):628.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"4110_CR87","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14(1):206.","journal-title":"Blood Cancer J"},{"issue":"6","key":"4110_CR88","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4110_CR89","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868.","journal-title":"Nat Commun"},{"issue":"18","key":"4110_CR90","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med. 2025;392(18):1777\u201388.","journal-title":"N Engl J Med"},{"issue":"1","key":"4110_CR91","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14(1):158.","journal-title":"Blood Cancer J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04110-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:28:03Z","timestamp":1782847683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04110-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4110"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04110-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yawara Kawano has received research funding from Sebia, has received honoraria from Janssen Pharmaceuticals Inc, Sebia, Ono Pharmaceutical, Takeda Pharmaceutical Co. Ltd., Bristol Myers Squibb Co., and Sanofi and has served on Advisory Board for Bristol Myers Squibb Co. Junzhe Bai and Nao Nishimura have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}